Innovative AI Technology for Enhanced Surgical Planning Debuts at ASBrS Meeting
SimBioSys Unveils TumorSight® Viz 1.4 at ASBrS Annual Meeting
At the American Society of Breast Surgeons (ASBrS) Annual Meeting, hosted from April 29 to May 3, 2026, in Seattle, WA, SimBioSys® is set to push the boundaries of surgical planning with the introduction of its latest innovation: TumorSight® Viz 1.4. This FDA-cleared AI-driven platform marks a significant advancement in how breast cancer surgeries are approached.
Enhancements for Personalized Surgical Planning
The TumorSight Viz platform has been pivotal in converting standard breast MRI data into interactive 3D visualizations tailored to individual patients. Surgeons benefit from deeper anatomical insights that inform more personalized surgical strategies. The new update, TumorSight Viz 1.4, introduces several key features aimed at enhancing usability and integration in clinical settings:
- - Enhanced Visualization and Measurement Tools: Improving the clarity and utility of visualization tools ensures surgical teams can plan procedures with greater accuracy and confidence.
- - Streamlined Case Intake: Enhancements in workflow efficiency allow for a more seamless experience, allowing healthcare professionals to quickly engage with patient data and improve operational productivity.
- - Enterprise-Ready Features: Designed for scalability and robust system management, these upgrades ensure the platform can be broadly adopted across hospitals and health systems, enhancing its impact.
New Tools for Comprehensive Surgical Outcomes
In addition to these functional updates, SimBioSys will introduce an innovative surgical outcome visualization capability. This breakthrough tool provides a glimpse of anticipated surgical results before the procedure, which broadens the scope of planning beyond just tumor anatomy. It actively involves surgical teams in discussions with patients about the expected outcomes, thus fostering shared decision-making processes.
Dr. Barry Rosen, Chief Medical Officer of SimBioSys, emphasizes the rising necessity of tools that assist surgeons in making informed decisions that align with patient goals, especially concerning both oncologic and aesthetic outcomes. As patient expectations evolve, the impact of precise, user-friendly technology has never been more critical.
At the ASBrS conference, attendees can gain firsthand experience with TumorSight Viz through interactive demonstrations and Meet the Experts sessions, featuring notable clinicians like Dr. Vincent Reid and Dr. Barry Rosen sharing insights on integrating AI technology into routine surgical practices.
About SimBioSys
SimBioSys, a leader in AI-driven precision medicine, focuses on transforming how we understand and treat cancer. By harnessing the power of AI, it empowers clinical practices with actionable insights drawn from standard medical imaging, enhancing the personalization of cancer treatment protocols. The TumorSight® Viz platform, along with the upcoming TumorSight® Risk solution, aims to deliver unparalleled confidence and precision, revolutionizing patient care methodologies.
Learn more about this groundbreaking technology and engage with the SimBioSys team at Booth #234 during the ASBrS Annual Meeting or visit www.simbiosys.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.